NCT07294508 2025-12-29
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
Clinical Trials
3 trialsNCT07294534 2025-12-19
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
NCT02568839 2020-08-13
PREDIX HER2
Karolinska University Hospital
Phase 2/3 Active not recruiting